Armando Anido
SCYNEXISAbout Armando Anido
Armando Anido, age 67 as of April 15, 2025, is an independent director of SCYNEXIS who joined the Board on January 21, 2019. He brings 30+ years of biopharmaceutical executive and commercial leadership, including CEO roles at Zynerba Pharmaceuticals (Chairman/CEO until its October 2023 sale to Harmony Biosciences), NuPathe (led FDA approval and pre-launch of Zecuity), and Auxilium, with prior senior commercial roles at MedImmune, GlaxoWellcome, and Lederle; he holds a BS in Pharmacy and an MBA from West Virginia University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Zynerba Pharmaceuticals | Chairman & CEO | Oct 2014 – Oct 2023 (acquired by HRMY) | Led company through growth; strategic oversight until sale |
| NuPathe Inc. | CEO & Director | Until Feb 2014 (sale to Teva) | Led FDA approval of Zecuity (migraine transdermal patch) and pre-launch |
| Auxilium Pharmaceuticals | President, CEO & Director | Not disclosed | Specialty pharma leadership; company later acquired by Endo |
| MedImmune | EVP, Sales & Marketing | Not disclosed | Senior commercial oversight |
| GlaxoWellcome | Senior sales/marketing roles | Not disclosed | Commercial leadership |
| Lederle Laboratories | VP, Anti-Infectives | Not disclosed | Commercialized antibacterials Suprax and Zosyn |
External Roles
| Organization | Role | Status |
|---|---|---|
| Altamira Therapeutics Ltd. (Nasdaq: CYTO; formerly Auris Medical Holding AG) | Director | Previously served |
| Life Science PA | Director | Previously served |
| Adolor Corporation | Director | Previously served; company sold to Cubist in Dec 2011 |
| Aviragen Therapeutics, Inc. | Director | Previously served |
Board Governance
- Independence: Board determined all directors other than the CEO are independent; Anido is independent .
- Committee assignments (2024): Compensation Committee member; Nominating and Corporate Governance Committee member; not a chair .
- Committee meeting cadence (2024): Audit 4; Compensation 6; Nominating 1 .
- Board leadership: Independent Chairman (Guy Macdonald) separate from CEO .
- Attendance: Board met five times in 2024; all directors attended at least 75% of Board and committee meetings, and all current directors attended the 2024 annual meeting .
- Executive sessions: Independent directors met in regularly scheduled executive sessions .
| Governance Item | Detail |
|---|---|
| Independence | Independent director (Nasdaq definition) |
| Committees | Compensation (member), Nominating & Corporate Governance (member) |
| Chair Roles | None (Compensation chair: S.C. Gilman; Nominating chair: A.F. Hanham) |
| 2024 Meetings | Board: 5; Committees: Audit 4, Compensation 6, Nominating 1 |
| Attendance | ≥75% of aggregate meetings; attended 2024 annual meeting |
| Board Leadership | Independent Chairman (separate from CEO) |
| Executive Sessions | Independent directors met regularly in executive session |
Fixed Compensation
| Component | Amount (USD) | Notes |
|---|---|---|
| 2024 Cash Fees (Anido) | $57,500 | Total cash earned in 2024 |
| Base Cash Retainer (policy) | $45,000 | Paid quarterly |
| Committee Fees (policy) | Compensation member: $7,500; Nominating member: $5,000 | Paid quarterly |
| Chair Fees (policy) | Audit chair: $20,000; Comp chair: $15,000; Nominating chair: $10,000 | Not applicable to Anido (not a chair) |
| Board Chair Add’l Retainer (policy) | $35,000 | Paid to Board Chairman (not Anido) |
Performance Compensation
- Structure: Annual director equity grants of 23,000 RSUs and options for 23,000 shares at FMV on grant date; both vest 100% at one-year anniversary. New directors receive initial grants of 46,000 RSUs and 46,000 options vesting over three years. Directors may elect fully vested nonstatutory options in lieu of cash compensation, calculated per policy formula; equity awards are time-based (no performance metrics) .
| Award/Metric | Detail |
|---|---|
| 2024 Stock Award Fair Value (Anido) | $43,240 |
| 2024 Option Award Fair Value (Anido) | $30,730 |
| Annual Director Grant Policy | RSU 23,000; Option 23,000; one-year cliff vest; exercise price = FMV on grant date |
| Cash-to-Option Election (Policy) | Option shares = (cash forgone ÷ 0.65) ÷ FMV; 100% vested at grant |
| 2025 Form 4 (Post-AGM) | Granted 23,000 RSUs (time-based, 1-year vest) and option for 23,000 shares at $0.74 strike, expiring June 25, 2035; post-grant directly owned shares 71,000 |
Other Directorships & Interlocks
| Company | Relationship | Potential Conflict |
|---|---|---|
| Zynerba Pharmaceuticals | Former Chairman & CEO; company sold Oct 2023 | None disclosed with SCYNEXIS |
| Altamira Therapeutics; Adolor; Aviragen; Life Science PA | Prior board service | None disclosed; no related-party transactions since 1/1/2023 |
Expertise & Qualifications
- Education: BS in Pharmacy; MBA (West Virginia University) .
- Domain expertise: Anti-infectives commercialization (Suprax, Zosyn); extensive sales/marketing leadership; FDA approval execution (Zecuity) .
- Board skills: Executive leadership, commercialization, governance; independent committee service (Compensation; Nominating) .
Equity Ownership
| Ownership Item | Amount | Notes |
|---|---|---|
| Beneficially Owned Shares | 72,000 | As of March 31, 2025 |
| Shares Acquirable within 60 Days | 47,000 | Options/warrants exercisable within 60 days |
| Ownership % of Outstanding | <1% | Less than 1% of 39,020,274 shares |
| RSUs Outstanding (12/31/2024) | 23,000 | Non-employee director table |
| Options Outstanding (12/31/2024) | 70,000 | Non-employee director table |
| Hedging/Pledging | Prohibited by Insider Trading Policy | No hedging, options on SCYX, margin accounts, or pledges allowed |
Insider Trades
| Date | Type | Security | Quantity | Price/Strike | Vest/Expiry | Post-Grant Holding |
|---|---|---|---|---|---|---|
| June 26, 2025 | Award (RSU) | RSU (time-based) | 23,000 | $0 | 100% on first anniversary | 71,000 direct shares after grant |
| June 26, 2025 | Award (Option) | Stock option | 23,000 | $0.74 strike | 100% on first anniversary; expires June 25, 2035 | 71,000 direct shares after grant |
Compensation Committee Analysis
- Composition: Independent directors Anido, S.C. Gilman (Chair), G. Macdonald .
- Consultant: Pearl Meyer engaged; reviewed director compensation competitiveness, grant value methodology, executive benchmarking, and equity guidelines .
- Process: Executive sessions; CEO excluded from self-comp deliberations; authority to retain advisers with independence considerations per SEC/Nasdaq factors .
Say-on-Pay & Shareholder Feedback
- 2024 Say-on-Pay support: For 13,476,050; Against 1,616,310; Abstain 369,042; Broker non-votes 10,498,371—indicating substantial investor support for compensation practices .
- 2024 director elections: Anido re-elected (For 14,119,574; Withheld 1,341,828; Broker non-votes 10,498,371) .
Related-Party Transactions
- Policy: Audit Committee pre-approval; threshold $120,000; review for arm’s-length terms .
- Disclosures: No related-person transactions with directors/NEOs since January 1, 2023 apart from standard compensation .
Governance Assessment
-
Strengths:
- Independent, experienced operator with commercialization track record; sits on Compensation and Nominating committees, supporting board effectiveness .
- Attendance and engagement are adequate (≥75% meetings; attended annual meeting); independent executive sessions occur regularly .
- Compensation alignment via routine, time-based equity grants; ability to elect options in lieu of cash increases at-risk pay; Pearl Meyer independent review of director compensation .
- No related-party transactions; stringent policy against hedging/pledging and margin accounts reduces misalignment risk .
- Investor support for compensation program reflected in strong say-on-pay approval .
-
Potential Red Flags:
- Time-based director equity without performance metrics; however, such structure is common for directors (noted for transparency) .
- Limited individual attendance disclosure (only ≥75% aggregate reported), reducing granularity on director-level engagement .
- Prior extensive roles in anti-infectives could present theoretical conflicts, but no related-party dealings are disclosed; Audit Committee screens such transactions .
Overall, Armando Anido’s independence, committee participation, and equity-based alignment support investor confidence; lack of performance-based director equity is standard, and no conflicts or pledging are disclosed under SCYNEXIS’s policies .